Literature DB >> 21846414

Failure of propranolol in the treatment of childhood haemangiomas of the head and neck.

J Goswamy1, M P Rothera, I A Bruce.   

Abstract

BACKGROUND: Infantile haemangiomas enter a rapid proliferative phase within months of birth, before slowly involuting. Those with the potential for disfigurement or morbidity require intervention. Propranolol has emerged as an effective new treatment modality, with the potential to become the first-line treatment of choice.
METHODS: Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre. The size of the haemangioma and the symptoms resulting from airway compromise were monitored.
RESULTS: Three of the four children showed a dramatic response to treatment with propranolol. However, one child responded initially but was readmitted with stridor secondary to new haemangioma proliferation.
CONCLUSIONS: We report a cautionary case in which a subglottic haemangioma developed contemporaneously with propranolol treatment, requiring surgical intervention. This finding highlights the need for regular follow up of treatment response, and the need for monitoring for treatment side effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21846414     DOI: 10.1017/S0022215111001538

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  4 in total

1.  A retrospective study to classify surgical indications for infantile hemangiomas.

Authors:  Andrew H Y Lee; Krista L Hardy; David Goltsman; Peter Liou; Maria C Garzon; Christine H Rohde; June K Wu
Journal:  J Plast Reconstr Aesthet Surg       Date:  2014-05-16       Impact factor: 2.740

Review 2.  Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.

Authors:  Beth A Drolet; Peter C Frommelt; Sarah L Chamlin; Anita Haggstrom; Nancy M Bauman; Yvonne E Chiu; Robert H Chun; Maria C Garzon; Kristen E Holland; Leonardo Liberman; Susan MacLellan-Tobert; Anthony J Mancini; Denise Metry; Katherine B Puttgen; Marcia Seefeldt; Robert Sidbury; Kendra M Ward; Francine Blei; Eulalia Baselga; Laura Cassidy; David H Darrow; Shawna Joachim; Eun-Kyung M Kwon; Kari Martin; Jonathan Perkins; Dawn H Siegel; Robert J Boucek; Ilona J Frieden
Journal:  Pediatrics       Date:  2012-12-24       Impact factor: 7.124

3.  A 24-Week Treatment of Pediatric Hemangioma with Oral Propranolol.

Authors:  Aziz Eghbali; Shabnam Hajiani; Bahman Sadeghi Sedeh; Abdolghader Pakniyat; Vahid Mansouri; Bahador Bagheri
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

4.  Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis.

Authors:  Ting Zhang; Yingying Qian; Chunyu Yuan; Yafen Wu; Hua Qian; Hui Lu; Cui Hu; Wei Li
Journal:  Biomed Res Int       Date:  2021-10-16       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.